Company research
SUPERNUS PHARMACEUTICALS, INC.
CIK 1356576Updated Sep 25, 2026
SecuritySUPN · NASDAQ · equity
Name history
SUPERNUS PHARMACEUTICALS INC · through Jun 12, 2019
SUPN price & chart
Loading TradingView…
NASDAQ:SUPN on TradingView ↗About the company
Supernus is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Supernus’ diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.
In the news
Shareholder Alert: Ademi LLP investigates whether Supernus Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders ↗
Supernus Announces Second Quarter 2026 Financial Results ↗
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc. News provided by Rowley Law PLLC Jun 16, 2025, 17:31 ET Share this article Share to X Share this article Share to X NEW YORK , June 16, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities l ↗
Recent filings
Show 5 more recent filings
Other Events
Items 8.01, 9.01
DEFA14A filing
425 filing
Other Events
Items 8.01, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 1,452,648,000Source | 1,368,073,000Source | 1,277,673,000Source | 1,702,508,000Source |
| Property, Plant and Equipment, NetUSD | 10,531,000Source | 11,545,000Source | 13,530,000Source | 15,173,000Source |
| GoodwillUSD | 124,882,000Source | 117,019,000Source | 117,019,000Source | 117,019,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 569,456,000Source | 521,912,000Source | 599,889,000Source | 702,463,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 128,448,000Source | 69,331,000Source | 75,054,000Source | 93,120,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 187,802,000Source | 142,077,000Source | 144,155,000Source | 165,497,000Source |
| Inventory, NetUSD | 112,480,000Source | 54,293,000Source | 77,408,000Source | 91,541,000Source |
| Assets, CurrentUSD | 644,182,000Source | 686,070,000Source | 493,113,000Source | 734,151,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 65,325,000Source | 36,088,000Source | 16,676,000Source | 15,779,000Source |
| Operating Lease, Right-of-Use AssetUSD | 26,712,000Source | 24,477,000Source | 28,994,000Source | 28,904,000Source |
| Other Assets, NoncurrentUSD | 63,796,000Source | 31,527,000Source | 37,505,000Source | 39,806,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 390,934,000Source | 332,340,000Source | 356,157,000Source | 816,304,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 57,000Source | 56,000Source | 55,000Source | 54,000Source |
| Additional Paid in CapitalUSD | 543,825,000Source | 479,440,000Source | 439,493,000Source | 408,115,000Source |
| Retained Earnings (Accumulated Deficit)USD | 517,876,000Source | 556,426,000Source | 482,561,000Source | 481,245,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -44,000Source | -189,000Source | -593,000Source | -3,210,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,061,714,000Source | 1,035,733,000Source | 921,516,000Source | 886,204,000Source |
| Liabilities and EquityUSD | 1,452,648,000Source | 1,368,073,000Source | 1,277,673,000Source | 1,702,508,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 338,171,000Source | 292,397,000Source | 290,196,000Source | 687,958,000Source |
| Operating Lease, Liability, CurrentUSD | 10,612,000Source | 6,889,000Source | 8,331,000Source | 6,791,000Source |
| Accounts Payable, CurrentUSD | 2,677,000Source | 4,587,000Source | 1,964,000Source | 10,543,000Source |
| Operating Lease, Liability, NoncurrentUSD | 30,365,000Source | 27,382,000Source | 33,196,000Source | 35,998,000Source |
| Deferred Income Tax Liabilities, NetUSD | 0Source | 4,961,000Source | 24,963,000Source | 49,809,000Source |
| Other Liabilities, NoncurrentUSD | 22,192,000Source | 7,600,000Source | 6,422,000Source | 8,692,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 107,800,000Source | 76,352,000Source | 79,569,000Source | 96,342,000Source |
| Deferred Tax Liabilities, NetUSD | — | 4,961,000Source | 24,963,000Source | 49,809,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 91,563,000Source | 80,414,000Source | 84,859,000Source | 85,543,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 33,051,000Source | 27,755,000Source | 26,759,000Source | 17,568,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 22,304,000Source | -2,078,000Source | -18,765,000Source | 16,366,000Source |
| Increase (Decrease) in InventoriesUSD | 7,502,000Source | -15,806,000Source | -6,110,000Source | 17,858,000Source |
| Deferred Income Tax Expense (Benefit)USD | 5,206,000Source | -20,136,000Source | -25,714,000Source | -26,324,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 47,331,000Source | 171,951,000Source | 111,085,000Source | 116,826,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 293,093,000Source | — | — | 0Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 4,106,000Source | -189,867,000Source | 268,729,000Source | -216,663,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,338,000Source | 725,000Source | 551,000Source | — |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 4,229,000Source | 2,715,000Source | 1,990,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 9,130,000Source | 12,193,000Source | -397,880,000Source | -10,477,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 60,567,000Source | -5,723,000Source | -18,066,000Source | -110,314,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 129,898,000Source | 69,331,000Source | 75,054,000Source | 93,120,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | 0Source | 1,946,000Source | 2,516,000Source |
| Income Taxes Paid, NetUSD | 16,051,000Source | 53,254,000Source | 36,602,000Source | 16,200,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 55,972,000Source | 27,755,000Source | 26,759,000Source | 17,568,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 0Source | 0Source | 532,000Source | 2,112,000Source |
| Amortization of Intangible AssetsUSD | 89,456,000Source | 77,977,000Source | 82,385,000Source | 82,630,000Source |
| DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecordedUSD | 0Source | 0Source | 0Source | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | -439,000Source | — | — | — |
| Equity Method Investment, Realized Gain (Loss) on DisposalUSD | — | 0Source | 0Source | 12,888,000Source |
| GoodwillUSD | 124,882,000Source | 117,019,000Source | 117,019,000Source | 117,019,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 0Source | 0Source | 20,189,000Source | — |
| Income Tax Expense (Benefit)USD | -10,480,000Source | 24,005,000Source | 1,453,000Source | 32,000Source |
| InterestExpenseNonoperatingUSD | 0Source | 0Source | 2,415,000Source | — |
| Inventory Write-downUSD | 1,926,000Source | 8,876,000Source | 8,023,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -38,550,000Source | 73,865,000Source | 1,316,000Source | 60,711,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -38,550,000Source | 73,865,000Source | 1,316,000Source | 64,267,000Source |
| Nonoperating Income (Expense)USD | 13,253,000Source | 16,204,000Source | 8,038,000Source | — |
| Other Nonoperating Income (Expense)USD | 13,253,000Source | 16,204,000Source | 10,453,000Source | 14,619,000Source |
| Proceeds from Issuance of Common StockUSD | 37,616,000Source | 14,908,000Source | 6,610,000Source | 12,423,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 774,478,000Source | 498,871,000Source | 370,901,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 34,900,000Source | 6,800,000Source | 4,300,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 718,952,000Source | 661,817,000Source | 607,521,000Source | 667,238,000Source |
| Cost of RevenueUSD | 74,562,000Source | 77,906,000Source | 83,779,000Source | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 485,563,000Source | 321,582,000Source | 336,361,000Source | 377,221,000Source |
| Operating Income (Loss)USD | -62,283,000Source | 81,666,000Source | -5,269,000Source | 46,124,000Source |
| Other Nonoperating Income (Expense)USD | 13,253,000Source | 16,204,000Source | 10,453,000Source | 14,619,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -49,030,000Source | 97,870,000Source | 2,769,000Source | 60,743,000Source |
| Income Tax Expense (Benefit)USD | -10,480,000Source | 24,005,000Source | 1,453,000Source | 32,000Source |
| Net Income (Loss) Attributable to ParentUSD | -38,550,000Source | 73,865,000Source | 1,316,000Source | 60,711,000Source |
| Earnings Per Share, BasicUSD per share | -0.68Source | 1.34Source | 0.02Source | 1.13Source |
| Earnings Per Share, DilutedUSD per share | -0.68Source | 1.32Source | 0.02Source | 1.04Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 56,451,136Source | 55,100,063Source | 54,536,281Source | 53,665,143Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 56,451,136Source | 55,958,537Source | 55,506,828Source | 61,679,800Source |
| Interest Expense (non-operating)USD | 0Source | 0Source | 2,415,000Source | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 89,456,000Source | 77,977,000Source | 82,385,000Source | 82,630,000Source |
| Cost of Goods and Service, Excluding Depreciation, Depletion, and AmortizationUSD | — | — | — | 87,221,000Source |
| Costs and ExpensesUSD | 781,235,000Source | 580,151,000Source | 612,790,000Source | 621,114,000Source |
| Current Income Tax Expense (Benefit)USD | -15,686,000Source | — | — | — |
| DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecordedUSD | 0Source | 0Source | 0Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 2,100,000Source | 2,400,000Source | 2,500,000Source | 3,000,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -48,825,000Source | — | — | — |
| Interest Expense, DebtUSD | 0Source | 0Source | 1,321,000Source | 4,654,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -38,550,000Source | 73,865,000Source | 1,316,000Source | 64,267,000Source |
| Nonoperating Income (Expense)USD | 13,253,000Source | 16,204,000Source | 8,038,000Source | — |
| Research and Development ExpenseUSD | 106,235,000Source | 108,796,000Source | 91,593,000Source | 74,552,000Source |
Filing attachments
tm2622009d7_ex99-1.htm · 8-K · 2026-08-03
EX-99.1 2 tm2622009d7_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Filed by: Supernus Pharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Supernus Pharmaceuticals, Inc. Commission File No. 001-35518 Date: August 3, 2026
Read attachment ↗tm2622009d7_ex99-2.htm · 8-K · 2026-08-03
EX-99.2 3 tm2622009d7_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Filed by: Supernus Pharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Supernus Pharmaceuticals, Inc. Commission File No.: 001-35518 Date: August 3, 2026 August, 3, 2026 ─────────────────── For Internal Use Only, Do Not Forward Dear Colleagues, Today, we announced that Supernus and Indivior have ent…
Read attachment ↗tm2622009d4_ex99-1.htm · 8-K · 2026-08-03
EX-99.1 2 tm2622009d4_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Filed by: Supernus Pharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Supernus Pharmaceuticals, Inc. Commission File No.: 001-35518 Date: August 3, 2026 Merger of Equals to Create a Diversified CNS Biopharmaceutical Leader with Significant Scale AUGUST 3, 2026 ──────────────────────────────── Fo…
Read attachment ↗tm2622009d1_ex99-1.htm · 8-K · 2026-08-03
EX-99.1 6 tm2622009d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Filed by: Supernus Pharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Supernus Pharmaceuticals, Inc. Commission File No.: 001-35518 Date: August 3, 2026 Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale · Combines…
Read attachment ↗tm2522014d3_ex99-1.htm · 8-K · 2025-07-31
EX-99.1 3 tm2522014d3_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid- to long-term revenue and cash flow growth and further diversifying revenue base ROCKVILLE, Md., July 31, 2025 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) (“Supern…
Read attachment ↗tm2518064d1_ex99-1.htm · 8-K · 2025-06-16
EX-99.1 3 tm2518064d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base. Strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform. Expected to be signifi…
Read attachment ↗